טוען...
Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
Esophageal squamous cell carcinoma (ESCC) is one of the common malignant tumors in the world. More than half of patients with ESCC were detected in advanced or metastatic disease at the time of initial diagnosis and lost the opportunities of surgery. Currently, surgical resection, radiotherapy, and...
שמור ב:
| הוצא לאור ב: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6677374/ https://ncbi.nlm.nih.gov/pubmed/31551657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S214579 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|